Marc van Dijk
Technik-/Wissenschafts-/F&E-Leiter bei MINK THERAPEUTICS, INC.
Vermögen: 23 833 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jennifer Buell | M | 50 | 3 Jahre | |
| Ulf Arne Wiinberg | M | 66 | 7 Jahre | |
| Robert Stein | M | 73 | - | |
| Barbara Ryan | F | 64 | 3 Jahre | |
| Brian Corvese | M | 67 | 7 Jahre | |
| Peter Behner | M | 61 | 3 Jahre | |
| Heather Boussios | F | - | - | |
| Garo Armen | M | 71 | 7 Jahre | |
| Hans Clevers | M | 67 |
University of Utrecht
| 35 Jahre |
| Christine Klaskin | F | 58 | 7 Jahre | |
| Christiaan de Wilde | M | - |
Fujirebio Europe NV
 Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 18 Jahre |
| Zack Armen | M | - | - | |
| Alexa Buffa | F | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Paul Magrez | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 6 Jahre |
| John Baldoni | M | 72 | 2 Jahre | |
| René Kuijten | M | 60 |
University of Utrecht
| 4 Jahre |
| Frank Morich | M | 69 |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 2 Jahre |
| Patrick de van der Schueren | M | - |
University of Utrecht
| 7 Jahre |
| Michel Baijot | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 5 Jahre |
| Jurgen Post | M | 67 |
University of Utrecht
| 4 Jahre |
| Patrick Jordan | M | - | 2 Jahre | |
| Vera Goossens | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 5 Jahre |
| Willem Jansonius | M | - |
University of Utrecht
| 6 Jahre |
| Jan Derck van Karnebeek | M | 57 |
University of Utrecht
| 3 Jahre |
| Steven ten Have | M | 56 |
University of Utrecht
| 3 Jahre |
| Monique Visser | M | - |
University of Utrecht
| 1 Jahre |
| John-Paul Schuirink | M | - |
University of Utrecht
| 4 Jahre |
| Peter Wijngaard | M | 61 |
University of Utrecht
| 2 Jahre |
| Geert Maertens | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 18 Jahre |
| Werner Cautreels | M | 71 |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 7 Jahre |
| Arjan Dorrestijn | M | - |
University of Utrecht
| 5 Jahre |
| André van Puijenbroek | M | - |
University of Utrecht
| 1 Jahre |
| Torben Lund-Hansen | M | 73 |
Genmab, Inc.
 Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Genmab, Inc. creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. It also offers products for cancer and autoimmune disorders. The company is headquartered in Princeton, NJ. | 7 Jahre |
| Agneta Svedberg | F | 61 |
Genmab, Inc.
Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Genmab, Inc. creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. It also offers products for cancer and autoimmune disorders. The company is headquartered in Princeton, NJ. | - |
| Leon J de Windt | M | - |
University of Utrecht
| 1 Jahre |
| Ad W. van Gorp | M | - |
University of Utrecht
| 1 Jahre |
| Adrianus van Wijk | M | 68 |
University of Utrecht
| 3 Jahre |
| Walter van Cauwenberge | M | - |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | - |
| Caroline Princen | F | 57 |
University of Utrecht
| 4 Jahre |
| Huaizhong Hu | M | - |
University of Utrecht
| 3 Jahre |
| Gerben Moolhuizen | M | 57 |
University of Utrecht
| 1 Jahre |
| Karin T. V. Bergstein | M | 57 |
University of Utrecht
| 2 Jahre |
| Walter Flamenbaum | M | 81 | 2 Jahre | |
| Wim Ottevaere | M | 68 |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | 14 Jahre |
| Maarten de Jong | M | - |
University of Utrecht
| 6 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Niederlande | 20 | 44,44% |
| Vereinigte Staaten | 16 | 35,56% |
| Belgien | 9 | 20,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Marc van Dijk
- Persönliches Netzwerk
